Merck Reports Topline Results From Phase 3 Atlas-UC Induction-Only Study Evaluating Tulisokibart Benzinga 13:13 Mon, 22 Jun Article paywall
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 Atlas-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Business Wire (Press Release) 11:49 Mon, 22 Jun
